Sarker J, Tice J, Rind D, Walton S
Appl Health Econ Health Policy. 2024; .
PMID: 39623116
DOI: 10.1007/s40258-024-00932-x.
Zulfikar B, Koc B, Sahin F, Sasmaz H, Kavakli K, Balkan C
Res Pract Thromb Haemost. 2024; 8(7):102588.
PMID: 39582809
PMC: 11585750.
DOI: 10.1016/j.rpth.2024.102588.
Oldenburg J, Hay C, Peyvandi F, Tagliaferri A, Holme P, Alvarez-Roman M
Eur J Haematol. 2024; 114(2):248-257.
PMID: 39434416
PMC: 11707817.
DOI: 10.1111/ejh.14309.
Konigs C, Motwani J, Jimenez-Yuste V, Blatny J
J Clin Med. 2024; 13(17).
PMID: 39274334
PMC: 11396640.
DOI: 10.3390/jcm13175121.
Zhang F, Zhou X, Hua B, He X, Li Z, Xiao X
Gene Ther. 2024; 31(11-12):544-552.
PMID: 39256611
DOI: 10.1038/s41434-024-00479-5.
Evaluation of Safety and Efficacy of Emicizumab Prophylaxis in Egyptian Pediatric Patients with Hemophilia A.
Hassan T, Zakaria M, Fathy M, Farag A, Abdelhady E, Gameil D
Turk J Haematol. 2024; 41(4):256-263.
PMID: 39169683
PMC: 11628768.
DOI: 10.4274/tjh.galenos.2024.2024.0220.
The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B.
Sarker J, Tice J, Rind D, Pearson S, Walton S
J Manag Care Spec Pharm. 2024; 30(8):868-872.
PMID: 39088338
PMC: 11293759.
DOI: 10.18553/jmcp.2024.30.8.868.
Exploring the relationship between condition severity and health-related quality of life in people with haemophilia A across Europe: a multivariable analysis of data from the CHESS II study.
Ferri Grazzi E, Hawes C, Camp C, Hinds D, OHara J, Burke T
Health Qual Life Outcomes. 2024; 22(1):58.
PMID: 39075533
PMC: 11288067.
DOI: 10.1186/s12955-024-02267-6.
Skeletal complications in patients with hemophilia: a single-center experience.
Bordbar M, Beigipour R, Tahami M, Zekavat O, Haghpanah S, Moshfeghinia R
J Orthop Surg Res. 2023; 18(1):907.
PMID: 38017431
PMC: 10685514.
DOI: 10.1186/s13018-023-04409-w.
Glanzmann Thrombasthenia Associated with Siderotic Synovitis and Arthropathy: A Case Report.
Alawad M, Abu-Tineh M, Alshurafa A, Al-Taie A, Yousaf A, Yassin M
J Blood Med. 2023; 14:563-567.
PMID: 37941894
PMC: 10629506.
DOI: 10.2147/JBM.S418937.
Short-term outcome of total knee replacement in a patient with hemophilia: A case report and review of literature.
Yin D, Lin J, Li Y, Chen P, Zeng M
World J Clin Cases. 2023; 11(12):2788-2795.
PMID: 37214564
PMC: 10198112.
DOI: 10.12998/wjcc.v11.i12.2788.
The Effects of Exercise Training on Physical Activity Level, Daily Living Activities, and Participation in Children with Hemophilia.
Atay C, Tarakci E, Yeldan I, Zulfikar B
Turk Arch Pediatr. 2023; 58(3):274-281.
PMID: 37144260
PMC: 10210629.
DOI: 10.5152/TurkArchPediatr.2023.22226.
Thrombin generation and implications for hemophilia therapies: A narrative review.
Sidonio Jr R, Hoffman M, Kenet G, Dargaud Y
Res Pract Thromb Haemost. 2023; 7(1):100018.
PMID: 36798897
PMC: 9926221.
DOI: 10.1016/j.rpth.2022.100018.
Nonreplacement therapy for hemophilia in low-income countries: experience from a prospective study in Ivory Coast.
Lambert C, Meite N, Kouassi G, Dohoma A, Bognini Akou S, Sanogo I
Res Pract Thromb Haemost. 2023; 7(1):100033.
PMID: 36785756
PMC: 9918414.
DOI: 10.1016/j.rpth.2022.100033.
Surgery for chronic arthropathy in people with haemophilia.
Chin B, Wee I, Syn N, ONeill G, Yap E, Koh P
Cochrane Database Syst Rev. 2022; 11:CD013634.
PMID: 36448638
PMC: 9710191.
DOI: 10.1002/14651858.CD013634.pub2.
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3.
Callaghan M, Asikanius E, Lehle M, Oldenburg J, Mahlangu J, Uguen M
Res Pract Thromb Haemost. 2022; 6(6):e12782.
PMID: 36171959
PMC: 9468791.
DOI: 10.1002/rth2.12782.
The evolution of physiotherapy in the multidisciplinary management of persons with haemophilia (PWH): A scoping review.
Boccalandro E, Begnozzi V, Garofalo S, Pasca S, Peyvandi F
Haemophilia. 2022; 29(1):11-20.
PMID: 36167324
PMC: 10086794.
DOI: 10.1111/hae.14661.
LongHest project: A prospective, observational study of extended half-life treatment in the musculoskeletal health of patients with severe haemophilia A.
Cuesta-Barriuso R, Perez-Llanes R, Donoso-Ubeda E, Ucero-Lozano R
Haemophilia. 2022; 28(5):857-864.
PMID: 35561281
PMC: 9541876.
DOI: 10.1111/hae.14592.
Effectiveness of physical exercise on postural balance in patients with haemophilia: A systematic review.
Chimeno-Hernandez A, Querol-Giner F, Perez-Alenda S, Nunez-Cortes R, Cruz-Montecinos C, Carrasco J
Haemophilia. 2022; 28(3):409-421.
PMID: 35363925
PMC: 9325530.
DOI: 10.1111/hae.14556.
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors.
Shapiro A, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Eichler H
Blood Adv. 2022; 6(11):3422-3432.
PMID: 35290453
PMC: 9198939.
DOI: 10.1182/bloodadvances.2021006403.